BRCA1 and acute myeloid leukemia: Though the use of only pediatric samples in this study is an admitted weakness, in vitro incubations of these AML cells with panobinostat demonstrated dose-dependent decreases in protein and/or transcript levels for BRCA1, CHK1, and RAD51 genes (Figure 1 and Table 1), suggesting that panobinostat suppresses the DDR in AML cells by decreasing BRCA1, CHK1, and RAD51 transcript levels.